AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Merus to Present Petosemtamab Data at AACR-NCI-EORTC Conference
ByAinvest
Monday, Oct 13, 2025 12:01 pm ET1min read
Merus has announced the selection of its abstract on petosemtamab in metastatic colorectal cancer for oral presentation at the AACR-NCI-EORTC International Conference. Preliminary data from the phase 2 trial of petosemtamab in combination with chemotherapy in first-line and second-line metastatic colorectal cancer and as monotherapy in heavily pretreated third-line disease will be presented. The abstracts will be available on the conference app on Wednesday, October 22, 2025, and the full presentations will be available on the Merus website.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet